Optimizerx CORP Form 4 insider transactions

Director Cathy Klema acquired 6,643 shares of OptimizeRx Corp through restricted stock units, which vest on the earlier of the first anniversary of the grant date or the next annual meeting.

Director James Paul Lang reports acquisition and disposal of OptimizeRx Corp (OPRX) common stock and restricted stock units.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting of restricted stock units and subsequent tax withholding.

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, files an amended Form 4 to correct an understatement of beneficially owned shares and an overstatement of shares withheld for tax obligations.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, files an amended Form 4 to correct the grant date of common stock and adjust the number of beneficially owned shares.

OptimizeRx CEO William Febbo was granted 15,000 restricted stock units that will vest on February 15, 2025.

Chief Product Officer Doug Besch acquired 4,000 restricted stock units of OptimizeRx Corp on February 15, 2024, which will vest on February 15, 2025.

Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports the acquisition of restricted stock units.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, reports the acquisition and disposal of common stock and grant of restricted stock units.

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the acquisition of 7,750 restricted stock units.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, files an amended SEC Form 4/A to correct an understatement of shares acquired and holdings following a restricted stock unit vesting.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, files an amendment to a previous Form 4 to correct an overstatement of shares withheld for tax obligations.

OptimizeRx CEO William Febbo was granted 60,000 restricted stock units on April 15, 2024, which will vest in three equal annual installments starting April 15, 2025.

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.

Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports the vesting and conversion of restricted stock units into common stock, along with a disposition of shares to cover tax obligations.